Want to see AU:NSB full AI Analyst Report?
NSB Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.19
Previous CloseN/A
Volume70.60K
Average Volume (3M)212.56K
Market Cap
AU$23.77M
Enterprise ValueAU$15.52
Total Cash (Recent Filing)AU$6.36M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding389,718,540
10 Day Avg. Volume289,679
30 Day Avg. Volume212,565
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.34
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits refinancing and interest-rate exposure, giving the company greater financial flexibility while it funds biotechnology development. This is a durable balance-sheet advantage, although it does not offset the need to finance ongoing operating losses.
Equity CushionA meaningful equity base provides a stronger solvency cushion than the company’s income statement alone would suggest. It can help absorb development volatility and reduce immediate balance-sheet stress, though recurring losses may erode this support over time.
Prior Cash GenerationPositive operating and free cash flow in 2024 demonstrates that cash generation has been possible, offering some evidence of operational potential. However, the subsequent reversal means this remains an unproven capability rather than a dependable funding source.
Bears Say
Inconsistent RevenueRepeated zero-revenue years indicate the company lacks a stable commercial base, leaving funding dependent on capital markets or other non-operating sources. This weakens earnings visibility and makes it difficult to support ongoing biotechnology investment through internally generated revenue.
Recurring LossesThe return to substantial losses after the 2024 profit suggests that profitability was not established and may have been non-recurring. Deep operating and EBITDA losses indicate ongoing expenditure without a stable commercial base, creating persistent pressure on equity and funding needs.
Accelerating Cash BurnDeteriorating operating cash flow and generally negative free cash flow show limited self-funding capacity. For a biotechnology company, sustained burn increases dependence on future financing and raises the risk that development activity will be constrained if capital becomes harder to secure.
Neuroscientific Biopharmaceuticals Ltd. News
NSB FAQ
What was Neuroscientific Biopharmaceuticals Ltd.’s price range in the past 12 months?
Neuroscientific Biopharmaceuticals Ltd. lowest share price was AU$0.06 and its highest was AU$0.19 in the past 12 months.
What is Neuroscientific Biopharmaceuticals Ltd.’s market cap?
Neuroscientific Biopharmaceuticals Ltd.’s market cap is AU$23.77M.
When is Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date?
Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 179 days.
How were Neuroscientific Biopharmaceuticals Ltd.’s earnings last quarter?
Neuroscientific Biopharmaceuticals Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.009 earnings per share for the quarter.
Is Neuroscientific Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Neuroscientific Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Neuroscientific Biopharmaceuticals Ltd. pay dividends?
Neuroscientific Biopharmaceuticals Ltd. does not currently pay dividends.
What is Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate?
Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuroscientific Biopharmaceuticals Ltd. have?
Neuroscientific Biopharmaceuticals Ltd. has 389,718,540 shares outstanding.
What happened to Neuroscientific Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Neuroscientific Biopharmaceuticals Ltd. reported an EPS of -AU$0.009 in its last earnings report. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Neuroscientific Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:NSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuroscientific Biopharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:NSB Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.49%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neuroscientific Biopharmaceuticals Ltd.
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Technical Analysis
Actinogen Medical
―
Neuren Pharmaceuticals Limited
―
Alterity Therapeutics
―
Zelira Therapeutics
―
PYC Therapeutics Limited
―